Literature DB >> 27190693

Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Shahinul Alam1, Golam Mustafa1, Mahabubul Alam1, Nooruddin Ahmad1.   

Abstract

Although insulin resistance (IR) is strongly associated with nonalcoholic fatty liver disease (NAFLD), the association of IR and NAFLD is not universal and correlation between IR and severity of NAFLD is still controversial. In this review, we summarize recent evidence that partially dissociates insulin resistance from NAFLD. It has also been reported that single-nucleotide polymorphisms in the diacylglycerol acyltransferase gene, rather than IR, account for the variability in liver fat content. Polymorphisms of the patatin-like phospholipase 3 gene have also been reported to be associated with NAFLD without metabolic syndrome, which suggests that genetic conditions that promote the development of fatty changes in the liver may occur independently of IR. Moreover, environmental factors such as nutrition and physical activity as well as small intestinal bacterial overgrowth have been linked to the pathogenesis of NAFLD, although some of the data are conflicting. Therefore, findings from both genetically engineered animal models and humans with genetic conditions, as well as recent studies that have explored the role of environmental factors, have confirmed the view that NAFLD is a polygenic disease process caused by both genetic and environmental factors. Therefore, IR is not the sole predictor of the pathogenesis of NAFLD.

Entities:  

Keywords:  Diabetes; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Year:  2016        PMID: 27190693      PMCID: PMC4867400          DOI: 10.4291/wjgp.v7.i2.211

Source DB:  PubMed          Journal:  World J Gastrointest Pathophysiol        ISSN: 2150-5330


  75 in total

Review 1.  Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Authors:  Mohamed Asrih; François R Jornayvaz
Journal:  Mol Cell Endocrinol       Date:  2015-02-24       Impact factor: 4.102

Review 2.  Non-alcoholic fatty liver disease and cardiovascular risk.

Authors:  Angel Brea; José Puzo
Journal:  Int J Cardiol       Date:  2012-11-09       Impact factor: 4.164

Review 3.  Extrahepatic complications of nonalcoholic fatty liver disease.

Authors:  Matthew J Armstrong; Leon A Adams; Ali Canbay; Wing-Kin Syn
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

4.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.

Authors:  I R Willner; B Waters; S R Patil; A Reuben; J Morelli; C A Riely
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

5.  Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.

Authors:  Hellan Kang; Joel K Greenson; Jason T Omo; Cewin Chao; Debra Peterman; Lilian Anderson; Laura Foess-Wood; Mary A Sherbondy; Hari S Conjeevaram
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

Review 6.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

7.  High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis.

Authors:  Jean-Marc Sabaté; Pauline Jouët; Florence Harnois; Charlotte Mechler; Simon Msika; Maggy Grossin; Benoît Coffin
Journal:  Obes Surg       Date:  2008-02-20       Impact factor: 4.129

8.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity.

Authors:  Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

Review 9.  Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.

Authors:  Chin Hee Kim; Zobair M Younossi
Journal:  Cleve Clin J Med       Date:  2008-10       Impact factor: 2.321

10.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

View more
  25 in total

1.  New Role of Hispidulin in Lipid Metabolism: PPARα Activator.

Authors:  Xinchi Wu; Juan Xu
Journal:  Lipids       Date:  2016-10-15       Impact factor: 1.880

2.  Relative skeletal muscle mass and non-alcoholic fatty liver disease: from association to causation.

Authors:  Hee Yeon Kim; Jong Young Choi; Yong-Moon Park
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

3.  Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease.

Authors:  Baran Ghezelbash; Nader Shahrokhi; Mohammad Khaksari; Gholamreza Asadikaram; Maryam Shahrokhi; Sara Shirazpour
Journal:  Chin J Integr Med       Date:  2022-03-08       Impact factor: 1.978

4.  The potential association between periodontitis and non-alcoholic fatty liver disease: a systematic review.

Authors:  Mohammad Sultan Alakhali; Sadeq Ali Al-Maweri; Hashem Motahir Al-Shamiri; Khaled Al-Haddad; Esam Halboub
Journal:  Clin Oral Investig       Date:  2018-10-24       Impact factor: 3.573

5.  Role of NCAN rs2228603 polymorphism in the incidence of nonalcoholic fatty liver disease: a case-control study.

Authors:  Meng-Juan Wu; Chen Yuan; Lin-Lin Lu; Bai-Quan An; Shi-Ying Xuan; Yong-Ning Xin
Journal:  Lipids Health Dis       Date:  2016-11-26       Impact factor: 3.876

6.  Associations between White Blood Cell Count and the Development of Incidental Nonalcoholic Fatty Liver Disease.

Authors:  Goh Eun Chung; Jeong Yoon Yim; Donghee Kim; Min-Sun Kwak; Jong In Yang; Su Jin Chung; Sun Young Yang; Joo Sung Kim
Journal:  Gastroenterol Res Pract       Date:  2016-12-13       Impact factor: 2.260

7.  Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance.

Authors:  Hannah E Da Silva; Anastasia Teterina; Elena M Comelli; Amel Taibi; Bianca M Arendt; Sandra E Fischer; Wendy Lou; Johane P Allard
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

Review 8.  Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.

Authors:  Giuseppe Della Pepa; Claudia Vetrani; Gianluca Lombardi; Lutgarda Bozzetto; Giovanni Annuzzi; Angela Albarosa Rivellese
Journal:  Nutrients       Date:  2017-09-26       Impact factor: 5.717

9.  Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.

Authors:  Kazushige Nirei; Hiroshi Matsumura; Mariko Kumakawa; Naoki Matsumoto; Hitomi Nakamura; Hiroaki Yamagami; Shunichi Matsuoka; Mitsuhiko Moriyama
Journal:  Int J Med Sci       Date:  2017-01-01       Impact factor: 3.738

Review 10.  Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.

Authors:  Nada Pejnovic; Ilija Jeftic; Nemanja Jovicic; Nebojsa Arsenijevic; Miodrag L Lukic
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.